Karyopharm Therapeutics (KPTI) Stock Price

$4.05 1.9%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    5

  • Fundamental

    2

  • Technical

    3

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Karyopharm Therapeutics, AI stock picks, stock alerts and much more.

Sign up

KPTI AI Stock Analysis

AI stock analysis for KPTI is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Karyopharm Therapeutics (KPTI) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Karyopharm Therapeutics (KPTI) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Karyopharm Therapeutics (KPTI), currently trading at $4.05, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About KPTI

LSE

  • Karyopharm Therapeutics Inc.

  • Symbol

    KPTI

  • Market

    NASDAQ

  • Industry

    Biotechnology

  • Market Cap

    35M

Similar Stocks

CPRX Catalyst Pharmaceuticals
CPRX		 $21.28
1.3%
7
INO Inovio Pharmaceuticals
INO		 $1.44
0.7%
2
MRNA Moderna
MRNA		 $32.15
1.6%
3
AVXL Anavex Life Sciences
AVXL		 $11.17
1.7%
5
BBIO BridgeBio Pharma
BBIO		 $45.62
1.5%
6

News

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
May 26, 2025. zacks.com
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?
May 19, 2025. zacks.com
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting
May 14, 2025. prnewswire.com
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results
May 13, 2025. benzinga.com

KPTI Alternative Data

Web Traffic

Karyopharm Therapeutics receives an estimated 6212 monthly visitors to karyopharm.com.

  • Web Traffic

    6212

  • Change from Previous Month

    20.9%

  • 3 Month Change

    10.7%

  • YoY Change

    10.7%

Twitter Followers

Karyopharm Therapeutics has 1,553 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.1% over the last month.

  • Twitter Followers

    1553

  • Daily Change

    0%

  • 1 Month Change

    0.1%

  • 3 Month Change

    0.1%

  • YoY Change

    0.1%

LinkedIn Followers

35,216 are following Karyopharm Therapeutics on LinkedIn, up by 0.6% over the last month.

  • LinkedIn Followers

    35216

  • Daily Change

    0%

  • 1 Month Change

    0.6%

  • 3 Month Change

    2.1%

Job Postings

Karyopharm Therapeutics has an estimated 5 open job postings, which is down -28.6% over the last month.

  • Job Postings

    5

  • Daily Change

    0%

  • 1 Month Change

    28.6%

  • 3 Month Change

    44.4%

  • YoY Change

    44.4%

LinkedIn Employees

According to LinkedIn, Karyopharm Therapeutics has 348 employees, down by -2.2% over the last month.

  • LinkedIn Employees

    348

  • Daily Change

    0.3%

  • 1 Month Change

    2.2%

  • 3 Month Change

    3.3%

  • YoY Change

    3.3%

Business Outlook

According to employee reviews, the business outlook among employees at Karyopharm Therapeutics is 70 out of 100 (bullish).

  • Business Outlook

    70

  • Change from Previous Month

    0%

  • 3 Month Change

    11.4%

  • YoY Change

    11.4%

Reddit Mentions

Karyopharm Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

News Mentions

Karyopharm Therapeutics was mentioned 0 times in the news yesterday.

  • News Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Facebook Engagement

Karyopharm Therapeutics has engaged 0 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

KPTI Financials

KPTI Key Metrics

  • Total Revenue

    $30.5M

  • Net Income

    -$30.8M

  • Earnings per Share

    $0.0924

  • Free cash flow

    -$25.8M

  • EBITDA

    -$19.6M

  • EBITDA Ratio

    -0.64187

  • Total Assets

    $164.4M

KPTI 2-year Revenue & Income
KPTI 2-year Free Cash Flow

KPTI Technicals

KPTI SMA
KPTI RSI

FAQ

What's the current price of Karyopharm Therapeutics (KPTI) Stock?
The price of an Karyopharm Therapeutics (KPTI) share is $4.05.

What's the market cap of Karyopharm Therapeutics?
The current market cap of Karyopharm Therapeutics is 35M.

Should I buy or sell KPTI?
Karyopharm Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Karyopharm Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.

Is Karyopharm Therapeutics a good investment?
The current analysis of Karyopharm Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Karyopharm Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy Karyopharm Therapeutics (KPTI) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Karyopharm Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to Karyopharm Therapeutics (KPTI) that investors often compare it to?
Karyopharm Therapeutics (KPTI) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.

What is the forecast for Karyopharm Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Karyopharm Therapeutics' stock price to be around $3.89 in 2026. Starting from the current price of $4.05, this represents a 4% change in price, indicating a bearish outlook for the stock.

How to buy Karyopharm Therapeutics (KPTI) Stock?
Karyopharm Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Karyopharm Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.